Overall, we found that SHP099 sensitized BRAFV600E mutant thyroid cancer cells to vemurafenib by relieving the reactivation of the MAPK/ERK and PI3K/AKT pathways. This evidence concerns the gene AKT1 and thyroid gland carcinoma.